Evidence map›Paper›PMID 37567612›Full record

ArticleJNCI cancer spectrum2023

Ki67 and breast cancer mortality in women with invasive breast cancer.

Jake Probert, David Dodwell, John Broggio, Jackie Charman, Mitch Dowsett, Amanda Kerr, Paul McGale, Carolyn Taylor, Sarah C Darby, Gurdeep S Mannu

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in JNCI cancer spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jake ProbertNuffield Department of Population Health, University of Oxford, Oxford, UK.
David DodwellNuffield Department of Population Health, University of Oxford, Oxford, UK.
John BroggioThe National Disease Registration Service, NHS England, Leeds, UK.
Jackie CharmanThe National Disease Registration Service, NHS England, Leeds, UK.
Mitch DowsettThe Institute of Cancer Research, London, UK.
Amanda KerrNuffield Department of Population Health, University of Oxford, Oxford, UK.
Paul McGaleNuffield Department of Population Health, University of Oxford, Oxford, UK.
Carolyn TaylorNuffield Department of Population Health, University of Oxford, Oxford, UK.
Sarah C DarbyNuffield Department of Population Health, University of Oxford, Oxford, UK.
Gurdeep S MannuNuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0003-0219-9474
University of Oxford · GBNHS EnglandInstitute of Cancer Research · GB

Funding

Cancer Research UKCancer Research UK C8225/A21133Cancer Research UK PRCRPG-NOV21\100001Cancer Research UK RCCCSF-NOV22/100002Department of Health
6 · The paper itself

Abstract

backgroundThe percentage of cells staining positive for Ki67 is sometimes used for decision-making in patients with early invasive breast cancer (IBC). However, there is uncertainty regarding the most appropriate Ki67 cut points and the influence of interlaboratory measurement variability. We examined the relationship between breast cancer mortality and Ki67 both before and after accounting for interlaboratory variability and 8 patient and tumor characteristics.

methodsA multicenter cohort study of women with early IBC diagnosed during 2009-2016 in more than 20 NHS hospitals in England and followed until December 31, 2020.

resultsKi67 was strongly prognostic of breast cancer mortality in 8212 women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early IBC (Ptrend < .001). This relationship remained strong after adjustment for patient and tumor characteristics (Ptrend < .001). Standardization for interlaboratory variability did little to alter these results. For women with Ki67 scores of 0%-5%, 6%-10%, 11%-19%, and 20%-29% the corresponding 8-year adjusted cumulative breast cancer mortality risks were 3.3% (95% confidence interval [CI] = 2.8% to 4.0%), 3.7% (95% CI = 3.0% to 4.4%), 3.4% (95% CI = 2.8% to 4.1%), and 3.4% (95% CI = 2.8% to 4.1%), whereas for women with Ki67 scores of 30%-39% and 40%-100%, these risks were higher, at 5.1% (95% CI = 4.3% to 6.2%) and 7.7% (95% CI = 6.6% to 9.1) (Ptrend < .001). Similar results were obtained when the adjusted analysis was repeated with omission of pathological information about tumor size and nodal involvement, which would not be available preoperatively for patients being considered for neoadjuvant therapy.

conclusionOur findings confirm the prognostic value of Ki67 scores of 30% or more in women with ER-positive, HER2-negative early IBC, irrespective of interlaboratory variability. These results also suggest that Ki67 may be useful to aid decision-making in the neoadjuvant setting.

Indexed as

Breast NeoplasmsBiomarkers, TumorCohort StudiesFemaleHumansKaplan-Meier EstimateKi-67 AntigenReceptors, EstrogenBiomarkers, TumorKi-67 AntigenReceptors, Estrogen

Identifiers

PMID37567612
PMCPMC10500622
OpenAlexW4385755853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.